News|Slideshows|January 18, 2018

Top 3 Hep C Studies for Primary Care

Highlights of 3 studies from 2017 that support the role of PCPs in HCV infection treatment, including prescribing direct-acting antiviral agents.

Three recent studies show the value of using direct-acting antiviral (DAA) agents to treat patients infected with hepatitis C virus (HCV), including treatment by primary care physicians:Â The majority of patients infected with HCV can be safely, effectively managed in a primary care setting.HCV viral load after four weeks of treatment with DAAs predicts sustained virologic response (SVR) in a real-world clinical setting.DAA therapy with sofosbuvir-based combinations safely and effectively treats HCV infection in patients with early-stage chronic kidney diseaseÂ

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Top 3 Hep C Studies for Primary Care

Related Content

ACOG Releases New Guidance on HIV Screening and Prevention

FDA Accepts Cefiderocol sNDA for Pediatric Gram-Negative Infections

7 Drugs Approved for Primary Care: Q2 2026

FDA Clears First Generic Baloxavir for Influenza Treatment, Postexposure Prophylaxis

Cognitive Rehabilitation Linked to Functional Gains in Long COVID Trial

Latest CME

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Washington

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – North Carolina

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Burst CME™: Transition from Pediatric to Adult Care in Sickle Cell Disease

Optimizing Lipid-Lowering Strategies for ASCVD Risk Reduction: Bridging the Gap in Treatment Intensification

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Advances in ALL Management Across the Patient Spectrum: Integrating Innovation and Precision Care

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

27th Annual International Lung Cancer Congress®

Project ECHO®: Advancing Care in Metastatic TNBC Through PD-L1–Informed Novel Frontline ADC Strategies

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

Looking Beneath the Surface: Latest Updates in Identifying and Managing Hypercortisolism in Patients with Type 2 Diabetes

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Tennessee

Minnesota Society of Clinical Oncology

South Carolina Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – North Carolina

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Montana/Wyoming

Breaking Down the Rationale for Targeting TROP2 in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Washington State Medical Oncology Society

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Nevada

Optimizing Treatment for Biliary Tract Cancers

24th Annual International Congress on the Future of Breast Cancer® East

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Cross-Disease Integration of Immunotherapy Innovations

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Collaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Houston Hematology Satellite Symposia

Radioligand Therapy 101: The Science Behind the Strategy

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Arkansas Association of Cancer Professionals

North Carolina Oncology Association

2026 Carolina Neuromuscular Disease Summit

Pathways to Progress: RAS in GI Cancers (Spotlight CE Session)

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Tackling Barriers to Vaccine Uptake: Practical Strategies for Adult Immunization

Cases and Conversations™: Mineralocorticoid Receptor Antagonists in Patients With HF—Augmenting Current Guidelines with Emerging Evidence

Burst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum